Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

被引:31
|
作者
Findlow, Jamie [1 ,2 ]
Bai, Xilian [1 ,2 ]
Findlow, Helen [1 ,2 ]
Newton, Emma [1 ,2 ]
Kaczmarski, Ed [1 ,2 ]
Miller, Elizabeth [3 ]
Borrow, Ray [1 ,2 ,4 ]
机构
[1] Publ Hlth England, Publ Hlth Lab, Manchester M13 9WZ, Lancs, England
[2] Manchester Royal Infirm, Manchester Med Microbiol Partnership, Manchester M13 9WZ, Lancs, England
[3] Publ Hlth England, Immunisat Dept, Hlth Protect Serv, London NW9 5EQ, England
[4] Univ Manchester, Inflammat Sci Res Grp, Sch Translat Med, Manchester M13 9PL, Lancs, England
关键词
Meningococcal; Vaccine; 4CMenB; ACWY-CRM; Laboratory workers; NEISSERIA-MENINGITIDIS SEROGROUP; IMMUNOLOGICAL HYPORESPONSIVENESS; POLYSACCHARIDE VACCINATION; GLYCOCONJUGATE VACCINE; UNITED-KINGDOM; HUMAN IMMUNITY; GROUP C; ANTIBODIES; ADULTS; STANDARDIZATION;
D O I
10.1016/j.vaccine.2015.05.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Safety precautions for laboratory staff working with meningococci should primarily rely on laboratory procedures preventing exposure to aerosols containing viable meningococci. Despite this, vaccination is a key component of protection in the occupational setting. In the UK in 2009, there were no licensed vaccines for meningococcal capsular group B or conjugate vaccines for capsular groups A, C, W and Y. We therefore undertook a Phase II trial in laboratory workers to investigate the safety and immunogenicity of a four component group B vaccine (4CMenB) and a quadrivalent group A, C,W and Y conjugate vaccine (ACWY-CRM). Enrolment was open to staff aged 18-65 years at the Public Health Laboratory, Manchester who may have had a potential occupational exposure risk to meningococci. 4CMenB was administered at 0,2 and 6 months in the non-dominant arm and ACWY-CRM concomitantly at 0 months in the dominant arm. Pre- and post-vaccination blood samples were taken and analysed by the serum bactericidal antibody (SBA) assay against A, C, W and Y strains and a panel of seven diverse group B strains. Diary cards were used to record any local and systemic reactions following each vaccination. In total, 38 staff were enrolled and received initial vaccinations with 31 completing the trial per protocol. Both vaccines were proven safe, with local reactogenicity being more commonly reported following 4CMenB than ACWY-CRM. High proportions of subjects had putative protective SBA titres pre-vaccination, with 61-84 and 61-87% protected against A, C, W and Y strains and diverse MenB strains, respectively. Post-vaccination, SBA titres increased with 95-100 and 90-100% of subjects with protective SBA titres against A, C, W and Y strains and diverse MenB strains, respectively. These data suggest that 4CMenB and ACWY-CRM are safe when administered concomitantly and have the potential to enhance protection for laboratory workers. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3322 / 3330
页数:9
相关论文
共 50 条
  • [1] Meningococcal Group B Vaccine (4CMenB) in Children
    Lopez-Lacort, Monica
    Munoz-Quiles, Cintia
    Orrico-Sanchez, Alejandro
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (22): : 2109 - 2109
  • [2] Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers
    Klein, Nicola P.
    Shepard, Julie
    Bedell, Lisa
    Odrljin, Tatjana
    Dull, Peter
    VACCINE, 2012, 30 (26) : 3929 - 3936
  • [3] Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children
    Castilla, J.
    Garcia Cenoz, M.
    Abad, R.
    Sanchez-Cambronero, L.
    Lorusso, N.
    Izquierdo, C.
    Canellas Llabres, S.
    Roig, J.
    Malvar, A.
    Gonzalez Carril, F.
    Boone, A. L. D.
    Perez Martin, J.
    Rodriguez Recio, M. J.
    Galmes, A.
    Caballero, A.
    Garcia Rojas, A.
    Juanas, F.
    Nieto, M.
    Viloria Raymundo, L. J.
    Martinez Ochoa, E.
    Rivas, A., I
    Castrillejo, D.
    Moreno Perez, D.
    Martinez, A.
    Borras, E.
    Sanchez Gomez, A.
    Pastor, E.
    Nartallo, V
    Arteagoitia, J. M.
    Alvarez-Fernandez, B.
    Garcia Pina, R.
    Fernandez Arribas, S.
    Vanrell, J.
    Garcia Hernandez, S.
    Mendoza, R. M.
    Mendez, M.
    Lopez-Tercero, M. M.
    Fernandez-Rodriguez, A.
    Blanco, A.
    Carrillo de Albornoz, F. J.
    Ruiz Olivares, J.
    Ruiz-Montero, R.
    Limia, A.
    Navarro-Alonso, J. A.
    Vazquez, J. A.
    Barricarte, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05): : 427 - 438
  • [4] Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
    Ladhani, Shamez N.
    Andrews, Nick
    Parikh, Sydel R.
    Campbell, Helen
    White, Joanne
    Edelstein, Michael
    Bai, Xilian
    Lucidarme, Jay
    Borrow, Ray
    Ramsay, Mary E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04): : 309 - 317
  • [5] Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
    Abitbol, Veronique
    Sohn, Woo-Yun
    Horn, Michael
    Safadi, Marco Aurelio P.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [6] Safety and Immunogenicity of Typhoid Fever and Yellow Fever Vaccines When Administered Concomitantly With Quadrivalent Meningococcal ACWY Glycoconjugate Vaccine in Healthy Adults
    Alberer, Martin
    Burchard, Gerd
    Jelinek, Tomas
    Reisinger, Emil
    Beran, Jiri
    Hlavata, Lucie Cerna
    Forleo-Neto, Eduardo
    Dagnew, Alemnew F.
    Arora, Ashwani K.
    JOURNAL OF TRAVEL MEDICINE, 2015, 22 (01) : 48 - 56
  • [7] Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia
    Marshall, H. S.
    Koehler, A. P.
    Wang, B.
    A'Houre, M.
    Gold, M.
    Quinn, H.
    Crawford, N.
    Pratt, N.
    Sullivan, T. R.
    Macartney, K.
    VACCINE, 2020, 38 (37) : 5914 - 5922
  • [8] Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB): a meta-analysis
    Flacco, M. E.
    Manzoli, L.
    Rosso, A.
    Marzuillo, C.
    Bergamini, M.
    Stefanati, A.
    Villari, P.
    Ricciardi, W.
    Ioannidis, J. P.
    Contopoulos-Ioannidis, D. G.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2017, 27
  • [9] A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)
    Marshall, Gary S.
    Abbing-Karahagopian, Victoria
    Marshall, Helen S.
    Cenci, Silvia
    Conway, James H.
    Occhipinti, Emilia
    Bekkat-Berkani, Rafik
    Banzhoff, Angelika
    Sohn, Woo-Yun
    EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 530 - 544
  • [10] The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy
    Rollier, Christine S.
    Dold, Christina
    Marsay, Leanne
    Sadarangani, Manish
    Pollard, Andrew J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (01) : 131 - 142